A Phase 4 interventional study of Cryoneurolysis and Botulinum toxin in Centreal Neurological Condition, Acquired Brain Injury (Including Stroke) and Multiple Sclerosis, sponsored by Oxford University Hospitals NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Oxford University Hospitals NHS Trust · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Brain Injuries with a site in United Kingdom — 5 open to participants now, 5 under way, none of them phase 3. Brain Injuries · United Kingdom.
Among the 40 studies in Brain Injuries with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 38th registered.
947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.
Browse Brain Injuries studies →5 of the 40 studies in Brain Injuries with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages 18+
Liverpool University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+
University College, London · Sites in United Kingdom
Ages 16+
University College, London · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 41 across 613 interventional studies indexed under Brain Injuries.
Median enrollment 28 across the 30 interventional studies, 73 across the 10 observational. Of the 26 that completed or were terminated, 5 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
Oxford University Hospitals NHS Trust is the lead sponsor of 94 studies on the registry; 6 are open to participants now.
Oxford University Hospitals NHS Trust has 2 studies filed under Brain Injuries — fewer than ten, so there is no comparison to draw.
1 of the studies in Brain Injuries with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07303582Oxford University Hospitals NHS TrustIndividualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Brain Injuries with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spasticity is an umbrella term for impairments of muscle tone and control in people with damage to the brain and spinal cord. It is highly prevalent and results in pain, stiffness, and contribute to difficulties in activities of daily living. Current treatment options are limited, and many people experience only partial reduction in spasticity and frequent repeated treatments are needed.
Cryoneurolysis is a medical technique which involves the controlled freezing of the nerves. It has been approved in the UK for the treatment of pain in the context of spasticity through the targeting of nerves which control problematic muscles. Oxford University Hospitals NHS Foundation Trust has been offering this treatment routinely since January 2024. This pilot study aims to improve the understanding of the potential effectiveness of this treatment and its potential side effects when compared with a more commonly used treatment (Botulinum Toxin).
Participants will be randomly allocated to receive usual care with Botulinum Toxin (control group) or usual care with Cryoneurolysis (intervention group). The investigators will assess pain, goal attainment, side effects, spasticity, disability and independence in daily activities, and movement of the arm and leg. Assessments will be at baseline and then 6-, 12-, 18-, and 24-weeks following treatment. Participants who are randomised to the control group will have the opportunity to receive cryoneurolysis treatment after the 12 week follow up assessment.
The results of this study will help to guide future studies to examine the effectiveness of this treatment.
Spasticity is an umbrella term for impairments of muscle activity and control in the context of damage or dysfunction in the central nervous system, occurring in up to 87% of spinal cord injury patients, 42% of stroke patients, and 80% of patients with multiple sclerosis. Spasticity results in pain, stiffness, and restrictions to activity including difficulties in personal care and mobility and a significant impact on quality of life.
Treatments including oral medications, botulinum toxin injections, and physical therapies can provide some degree of relief, but effectiveness varies widely. Many patients experience only partial reduction in spasticity, contributing to ongoing functional limitations. Botulinum toxin injections provide temporary relief necessitating frequent treatments (every 3-4 months). This is burdensome for patients and healthcare providers, with associated time and treatment costs. Pharmacological treatments can lead to systemic side effects including drowsiness, dizziness, and cognitive impairments. Surgical interventions are resource-intensive and require specialised medical facilities. Their associated costs, in terms of financial resources and healthcare infrastructure, significantly limit access for certain patients.
Cryoneurolysis, a novel medical technique, involves the controlled freezing of nerve tissue to temporarily disrupt its function. While primarily used for pain, there is a growing interest in its application for managing spasticity and it is currently approved for the treatment of pain in the context of spasticity at Oxford University Hospitals NHS Trust. Observational studies suggest immediate relaxation of the affected muscles, resulting in improved joint range of motion, enhanced functional mobility, and reduced pain. The investigators' own open-label proof-of-principle clinical data suggest the potential for substantial improvements in the impact of spasticity on quality of life.
This pilot randomised controlled study aims to improve the understanding of the potential clinical effectiveness and side effect profile of cryoneurolysis as a treatment for pain in the context of spasticity in people with a range of neurological conditions (e.g. acquired brain injury (ABI), spinal cord injury, stroke, multiple sclerosis).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Cryoneurolysis
Procedure: Botulinum toxin
Nerves that require treatment, and the number of treatments required for each nerve will be identified by routine clinical judgement. Nerve targets are identified using an ultrasound machine. The handheld Iovera cryoneurolysis device will be used for treatment. Participants will receive up to 4 treatments of cryoneurolysis for each nerve or nerve branch that requires treatment. It is anticipated that participants will have between 1 and 5 nerves or nerve branches per limb treated. Each Cryoneurolysis treatment takes 110 seconds. Total treatment time will be determined by number of nerves targeted and number of cryoneurolysis treatments per nerve. The shortest duration, with setup, is likely to be 60 minutes and the longest 120 minutes.
Also known as: Iovera, Cryoneurotomy, Cryoneurectomy, Cryoanalgesia
Muscles that require treatment with Botulinum Toxin will be identified by routine clinical assessment. Muscle targets will be identified using an ultrasound machine. It is anticipated that participants will have between 2 and 8 muscles identified for target. The participant will receive up to 200 units of Xeomin (Botulinum Toxin) per muscle that requires treatment. Treatment session of Botulinum Toxin will take 60 to 90 minutes.
Also known as: Botox, Xeomin, Chemodenervation, BoNT-A
Goal Attainment Scale
An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected).
Time frame: 6-weeks post-treatment
Self-reported Pain
Self-report, as measured by a numerical rating scale (range 0 - 10, higher scores indicating higher pain levels).
Time frame: 6, 12, 18, and 24 weeks post-treatment
Douleur Neuropathique en 4 (DN4)
Questionnaire used to determine whether pain is neuropathic in origin (range 0 - 10; a score of 4 or more suggests the presence of neuropathic pain).
Time frame: 6, 12, 18, and 24 weeks post-treatment
Neuropathic Pain Symptom Inventory (NPSI)
Questionnaire used to quantify neuropathic pain (range 0 - 100, higher scores reflect worse neuropathic pain).
Time frame: 6, 12, 18, and 24 weeks post-treatment
Side Effects
As measured by self-report side effects questionnaire
Time frame: 6, 12, 18, and 24 weeks post-treatment
Goal Attainment Scale
An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected).
Time frame: 12-weeks post treatment
Modified Ashworth Scale
Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased in tone).
Time frame: 6- and 12-weeks post treatment
Modified Tardieu Scale
Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased resistance).
Time frame: 6- and 12-weeks post treatment
Spasticity
Directly assessed by measuring the muscle activity to a passive stretch
Time frame: 6- and 12-weeks post treatment
Range of Motion
Assessed using a goniometer
Time frame: 6- and 12-weeks post treatment
Patient Reported Impact of Spasticity Measure (PRISM)
Questionnaire assessing spasticity related quality of life (41 items that describe impacts of spasticity, each of which is rated on a scale of 0-4 from "never true for me" to "very often true for me").
Time frame: 6- and 12-weeks post treatment
EQ5D
Questionnaire assessing quality of life across 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels which are scored 1 - 5, with higher scores indicating worse outcome.
Time frame: 6- and 12-weeks post treatment
Spasticity Related Quality of Life instrument (SQoL-6D)
Questionnaire assessing spasticity related quality of life (range 0 - 24, higher score indicating worse condition)
Time frame: 6- and 12-weeks post treatment
Barthel Index
Scale measuring a person's ability to complete activities of daily living (range 0 - 100, higher scores indicating more independence)
Time frame: 6- and 12-weeks post treatment
Gait assessment - Walking Speed
Kinematic assessment of lower extremity function, using EMG and motion capture cameras. Walking speed is measured in meters per second (m/s), with slower speed indicating worse outcome.
Time frame: 6- and 12-weeks post treatment
Gait assessment - Gait profile score
Kinematic assessment of lower extremity function using EMG and motion capture cameras. The gait profile score is measured in degrees, with higher scores indicating more abnormality, and no maximum score.
Time frame: 6- and 12-weeks post treatment
Leg Activity Measure (LEG-A)
Questionnaire assessing lower extremity function (3 sections: Section A range: 0-36; Section B range 0-60; Section C range 0 - 36. Higher score indicates more difficulty/severity.)
Time frame: 6- and 12-weeks post treatment
Shriners Hospital Upper Extremity Evaluation (SHUEE)
Kinematic assessment of upper extremity function using motion capture cameras.
Time frame: 6- and 12-weeks post treatment
Arm Activity Measure (ARM-A)
Questionnaire assessing upper extremity function (2 sections: Section A range: 0-32; Section B range 0-52. Higher score indicates more difficulty.)
Time frame: 6- and 12-weeks post treatment
Functional Assessment Test for Upper Limb (FAST-UL)
Assessment of upper extremity function (selected movements assessed and scored between 0 - 3, with higher scores indicating ability to complete movement more fully).
Time frame: 6- and 12-weeks post treatment
Pressure Pain Thresholds (PPT)
Sensory testing using a manual algometer to assess pain thresholds.
Time frame: 6, 12, 18, and 24 weeks post-treatment
Feedback Questionnaire/Interview
Qualitative feedback using either a semi-structured interview or a self-reported questionnaire (using the same questions as interview schedule), as per preference of participant, used to explore the satisfaction, experience, and anticipated barriers/facilitators to clinical implementation for the treatments.
Time frame: 24 weeks post treatment
Sleep Condition Indicator
Questionnaire assessing self-reported insomnia symptoms (range 0-32, higher numbers indicate less symptoms of insomnia)
Time frame: 6, 12, 18, and 24 weeks post-treatment
Goal Attainment Scale
An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected).
Time frame: 18- and 24-weeks post-treatment
Modified Ashworth Scale
Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased in tone).
Time frame: 18- and 24-weeks post-treatment
Modified Tardieu Scale
Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased resistance).
Time frame: 18- and 24-weeks post-treatment
Spasticity
Directly assessed by measuring the muscle activity to a passive stretch
Time frame: 18- and 24-weeks post-treatment
Range of motion
Assessed using a goniometer
Time frame: 18- and 24-weeks post-treatment
Patient Reported Impact of Spasticity Measure (PRISM)
Questionnaire assessing spasticity related quality of life (41 items that describe impacts of spasticity, each of which is rated on a scale of 0-4 from "never true for me" to "very often true for me")
Time frame: 18- and 24-weeks post-treatment
EQ5D
Questionnaire assessing quality of life across 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels which are scored 1 - 5, with higher scores indicating worse outcome.
Time frame: 18- and 24-weeks post-treatment
Spasticity Related Quality of Life instrument (SQoL-6D)
Questionnaire assessing spasticity related quality of life (range 0 - 24, higher score indicating worse condition)
Time frame: 18- and 24-weeks post-treatment
Barthel Index
Scale measuring a person's ability to complete activities of daily living (range 0 - 100, higher scores indicating more independence)
Time frame: 18- and 24-weeks post-treatment
Leg Activity Measure (LEG-A)
Questionnaire assessing lower extremity function (3 sections: Section A range: 0-36; Section B range 0-60; Section C range 0 - 36. Higher score indicates more difficulty/severity.)
Time frame: 18- and 24-weeks post-treatment
Arm Activity Measure (ARM-A)
Questionnaire assessing upper extremity function (2 sections: Section A range: 0-32; Section B range 0-52. Higher score indicates more difficulty.)
Time frame: 18- and 24-weeks post-treatment
Plan to share: Yes — De-identified data are available upon reasonable request.
Supporting information: Study protocol
Time frame: Following publication of results
Access criteria: Available upon reasonable request
Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion May 2026 → Nov 2027 and completion Nov 2026 → Apr 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oxford University Hospitals NHS Trust